Patient
Medicine and Dentistry
100%
Hepatitis B Virus
Immunology and Microbiology
54%
Hepatitis C Virus
Immunology and Microbiology
33%
Hepatocellular Carcinoma
Medicine and Dentistry
33%
Amino Acid
Medicine and Dentistry
28%
Combination Therapy
Medicine and Dentistry
28%
Plasma
Medicine and Dentistry
22%
Inpatient
Medicine and Dentistry
21%
Saito, A. ,
Kikuchi, M. ,
Matsumoto, Y. ,
Sugawara, E. ,
Takao, G. ,
Inomata, H. ,
Takahashi, A. ,
Sato, Y. ,
Kumondai, M. ,
Sato, Y. ,
Sato, T. ,
Ninomiya, M. ,
Inoue, J. ,
Maekawa, M. &
Mano, N. ,
2022 12月 1 ,
In: Therapeutic drug monitoring. 44 ,
6 ,
p. 771-776 6 p. 研究成果: Article › 査読
Lenvatinib
100%
Liver Cell Carcinoma
33%
Electrospray Ionization
16%
Therapeutic Drug Monitoring
16%
Anticarcinogen
8%
Fujita, M. ,
Abe, K. ,
Kuroda, H. ,
Oikawa, T. ,
Ninomiya, M. ,
Masamune, A. ,
Okumoto, K. ,
Katsumi, T. ,
Sato, W. ,
Iijima, K. ,
Endo, T. ,
Fukuda, S. ,
Tanabe, N. ,
Numao, H. ,
Takikawa, Y. ,
Ueno, Y. &
Ohira, H. ,
2022 12月 ,
In: Scientific reports. 12 ,
1 , 6479.
研究成果: Article › 査読
Liver Cell Carcinoma
100%
Lenvatinib
100%
Atrophy
80%
Prognosis
60%
Overall Survival
60%
Hepatocellular Carcinoma
100%
Liver Cell Carcinoma
100%
Alanine Aminotransferase
50%
Alanine
50%
Patient
41%
Kuroda, H. ,
Oikawa, T. ,
Ninomiya, M. ,
Fujita, M. ,
Abe, K. ,
Okumoto, K. ,
Katsumi, T. ,
Sato, W. ,
Igarashi, G. ,
Iino, C. ,
Endo, T. ,
Tanabe, N. ,
Numao, H. ,
Fukuda, S. ,
Iijima, K. ,
Masamune, A. ,
Ohira, H. ,
Ueno, Y. &
Takikawa, Y. ,
2022 7月 15 ,
In: Liver Cancer. 11 ,
4 ,
p. 383-396 14 p. 研究成果: Article › 査読
Lenvatinib
100%
Chemoembolization
91%
Transcatheter Arterial Chemoembolization
91%
Combination Therapy
83%
Patient
50%
Sato, K. ,
Inoue, J. ,
Akahane, T. ,
Kobayashi, T. ,
Takai, S. ,
Nakamura, T. ,
Sato, T. ,
Kimura, O. ,
Ninomiya, M. ,
Iwata, T. ,
Sano, A. ,
Tsuruoka, M. ,
Onuki, M. ,
Sawahashi, S. ,
Niitsuma, H. &
Masamune, A. ,
2022 ,
In: Tohoku Journal of Experimental Medicine. 258 ,
4 ,
p. 277-285 9 p. 研究成果: Article › 査読
Hepatitis B Virus
100%
Virus DNA
87%
DNA Virus
87%
Tenofovir Alafenamide
75%
Tenofovir
75%